High dose naltrexone for dyskinesias induced by levodopa

Ten patients with Parkinson's disease and levodopa induced dyskinesias (LIDs) took part in this randomised, placebo controlled, double blind, crossover trial to assess the efficacy and tolerability of high dose oral naltrexone for LIDs in Parkinson's disease. Patients received naltrexone (...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neurology, neurosurgery and psychiatry neurosurgery and psychiatry, 2001-04, Vol.70 (4), p.554-556
Main Authors: Manson, A J, Katzenschlager, R, Hobart, J, Lees, A J
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Analgesics
Biological and medical sciences
Diaries
Dose-Response Relationship, Drug
Drug therapy
Dyskinesia, Drug-Induced - drug therapy
Family medical history
Female
Humans
Levodopa - adverse effects
levodopa induced dyskinesias
Male
Medical sciences
Methods
Middle Aged
Naltrexone
Naltrexone - administration & dosage
Narcotics
Neurology
Neuropharmacology
Parkinson's disease
Patients
Pharmacology. Drug treatments
Psychiatry
Psychomotor disorders
Ratings & rankings
Reproducibility of Results
Short Report
Studies
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ten patients with Parkinson's disease and levodopa induced dyskinesias (LIDs) took part in this randomised, placebo controlled, double blind, crossover trial to assess the efficacy and tolerability of high dose oral naltrexone for LIDs in Parkinson's disease. Patients received naltrexone (5 mg/kg/day) or placebo for 2.5 weeks with 1 week wash out in between. Dyskinesias and motor function were assessed with a levodopa challenge, unified Parkinson's disease rating scale (UPDRS), the unified dyskinesia rating scale (UDRS), and patient diaries. Eight patients completed the trial. There was a small reduction in LIDs measured by patient diaries with naltrexone (20.5 (SD 24.9)%) compared with placebo (−4.1 (SD 22.6)%), p
ISSN:0022-3050
1468-330X
DOI:10.1136/jnnp.70.4.554